Metastatic Castration-Resistant Prostate Carcinoma Tissue Microarray | ArraysBank

Introduction

Metastatic castration-resistant prostate carcinoma (mCRPC) remains one of the most challenging stages of prostate cancer, representing disease progression despite androgen deprivation therapy. To accelerate research in oncology, reliable and well-characterized human samples are critical. ArraysBank now offers a tissue microarray (TMA) of 100 mCRPC adenocarcinoma cases, designed to provide investigators with standardized material for biomarker validation, therapeutic studies, and translational research.

What This Tissue Microarray Includes

The mCRPC tissue microarray is carefully constructed to maximize research value and reproducibility. Each case contributes a single representative core, enabling high-throughput screening and comparison.

Key features include:

• 100 cases of metastatic prostate adenocarcinoma

• Single core per case to streamline experimental consistency

• Detailed pathological information for each case:

  • Gleason Score & Gleason Grade

  • Preoperative medication history (including androgen deprivation or other neoadjuvant therapies)

  • Metastatic location (bone, lymph node, liver, lung, etc.)

  • Immunohistochemical (IHC) results for key biomarkers

This comprehensive dataset ensures that scientists can correlate molecular findings with clinical outcomes and pathological features.

Why Use a Tissue Microarray for mCRPC Research?

The tissue array format offers unique advantages over individual slides or blocks:

• Efficiency – Hundreds of cases can be studied in parallel on a single slide.

• Comparability – Uniform processing reduces variability between samples.

• Clinical Relevance – Each core is annotated with critical clinical and pathological parameters, making results more translational.

• Cost-effectiveness – Researchers save time and resources compared to sourcing individual specimens.

Applications in Prostate Cancer Research

The mCRPC tissue microarray is suitable for multiple research applications, including:

• Biomarker discovery and validation – Linking IHC results to Gleason Scores and metastatic sites.

• Drug development – Assessing therapeutic targets in castration-resistant prostate cancer tissue.

• Precision oncology – Studying patient variability based on medication history and metastatic progression.

• Educational use – Supporting medical training in pathology and oncology.

Quality Assurance at ArraysBank

All tissue microarrays at ArraysBank are prepared under strict quality standards. Each block undergoes:

• Ethical and IRB-compliant sourcing

• H&E staining and pathologist verification

• Multi-layer quality control for tissue integrity and annotation accuracy

• Secure storage and shipping protocols to preserve antigenicity

Conclusion

The mCRPC tissue microarray with 100 adenocarcinoma cases provides an unparalleled tool for prostate cancer researchers. With detailed Gleason scoring, treatment history, metastatic site data, and immunohistochemistry results, this product enables deeper understanding of disease mechanisms and supports the development of new therapeutic strategies.